PMID- 35933643
OWN - NLM
STAT- MEDLINE
DCOM- 20220915
LR  - 20220923
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 148
IP  - 10
DP  - 2022 Oct
TI  - A novel TMTC2-NTRK3 fusion in undifferentiated high-grade pleomorphic sarcoma.
PG  - 2933-2937
LID - 10.1007/s00432-022-04249-x [doi]
AB  - Undifferentiated high-grade pleomorphic sarcoma (UHPS) is a rare soft tissue 
      sarcoma (STS) originated from mesenchyme. UHPS is mostly advanced, aggressive and 
      has poor prognosis. Patients with UHPS tend to have a lower 5-year survival rate 
      than patients with other types of STS. NTRK fusions are commonly found in rare 
      histological tumor types. Among sarcomas, 90% of infantile fibrosarcomas have 
      NTRK fusions. Many other types of sarcomas have also been studied for NTRK 
      fusions. Targeted therapy with NTRK inhibitors, such as Larotrectinib and 
      Entrectinib, leads to response in most patients with NTRK1/2/3 gene 
      fusion-positive tumors. Herein, we present a 68-years old man with UHPS by 
      pathological diagnosis. Next-generation sequencing (NGS) revealed a novel 
      TMTC2-NTRK3 fusion, which was also detected by immunohistochemistry (IHC) and 
      fluorescence in situ hybridization (FISH). This report broadens the spectrum of 
      NTRK fusions in UHPS and highlights a new target for treatment.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Bai, Chujie
AU  - Bai C
AD  - Department of Bone and Soft Tissue Tumor, Key Laboratory of Carcinogenesis and 
      Translational Research (Ministry of Education), Peking University Cancer Hospital 
      and Institute, Beijing, 100143, China.
FAU - Zhang, Lu
AU  - Zhang L
AD  - Department of Bone and Soft Tissue Tumor, Key Laboratory of Carcinogenesis and 
      Translational Research (Ministry of Education), Peking University Cancer Hospital 
      and Institute, Beijing, 100143, China.
FAU - Wang, Yaohui
AU  - Wang Y
AD  - Department of Trauma, The Beijing Water Conservancy Hospital, Beijing, China.
FAU - You, Xia
AU  - You X
AD  - The State Key Lab of Translational Medicine and Innovative Drug Development, 
      Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, 210023, China.
FAU - Ju, Yongzhi
AU  - Ju Y
AD  - The State Key Lab of Translational Medicine and Innovative Drug Development, 
      Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, 210023, China.
FAU - Sun, Tingting
AU  - Sun T
AD  - The State Key Lab of Translational Medicine and Innovative Drug Development, 
      Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, 210023, China.
FAU - Fan, Zhengfu
AU  - Fan Z
AD  - Department of Bone and Soft Tissue Tumor, Key Laboratory of Carcinogenesis and 
      Translational Research (Ministry of Education), Peking University Cancer Hospital 
      and Institute, Beijing, 100143, China. fanzhengfu05@163.com.
LA  - eng
PT  - Case Reports
PT  - Letter
DEP - 20220807
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Carrier Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (NTRK3 protein, human)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (TMTC2 protein, human)
RN  - EC 2.7.10.1 (Receptor, trkC)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/genetics
MH  - *Bone Neoplasms
MH  - Carrier Proteins/genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Membrane Proteins/genetics
MH  - Oncogene Proteins, Fusion/genetics
MH  - Receptor, trkC/genetics
MH  - *Sarcoma/genetics/pathology
MH  - *Soft Tissue Neoplasms/drug therapy/genetics
OTO - NOTNLM
OT  - Sarcoma
OT  - TMTC2-NTRK3
OT  - Undifferentiated high-grade pleomorphic sarcoma (UHPS)
EDAT- 2022/08/08 06:00
MHDA- 2022/09/16 06:00
CRDT- 2022/08/07 13:58
PHST- 2022/05/09 00:00 [received]
PHST- 2022/08/02 00:00 [accepted]
PHST- 2022/08/08 06:00 [pubmed]
PHST- 2022/09/16 06:00 [medline]
PHST- 2022/08/07 13:58 [entrez]
AID - 10.1007/s00432-022-04249-x [pii]
AID - 10.1007/s00432-022-04249-x [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2022 Oct;148(10):2933-2937. doi: 
      10.1007/s00432-022-04249-x. Epub 2022 Aug 7.